Singapore, Nov. 13 -- Taiwan-based EirGenix Inc. has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG for the commercialisation of its independently developed breast cancer biosimilar, EG1206A (Pertuzumab Biosimilar to Roche Perjeta(R)), covering all territories except Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, the Philippines, and Japan.

The agreement further strengthens the two companies' collaborative development of the HER2 biosimilar product. Under the terms of the agreement, EirGenix will receive a total up to$152 million of upfront and milestone payments. In addition, EirGenix will also be entitled to a profit share once...